title: Chlorambucil synergizes with purine analogs in inducing in vitro cytotoxicity in B-cell chronic lymphocytic leukemia.
abstract: Combinations of different drug concentrations of CLB + FAMP and CLB + 2-CDA were synergistic in, respectively, 42.9% and 34.8%. At leukemic cell survival < or = 50%, 16.4% and 23.4% of all combinations were synergistic in the 2-CDA and FAMP groups, respectively. A significantly higher mean value of antagonistic interactions was observed in the 2-CDA group (p = 0.037).
authors.forename: I
authors.initials: I
authors.lastname: Callea
authors.forename: G
authors.initials: G
authors.lastname: Console
authors.forename: G
authors.initials: G
authors.lastname: Sculli
authors.forename: M
authors.initials: M
authors.lastname: Filangeri
authors.forename: G
authors.initials: G
authors.lastname: Messina
authors.forename: F
authors.initials: F
authors.lastname: Morabito
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D002699:Chlorambucil / Q000494:pharmacology*; D017338:Cladribine / Q000494:pharmacology*; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000473:pathology*; D014411:Neoplastic Stem Cells / Q000187:drug effects*; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D002699:Chlorambucil; D017338:Cladribine; D014740:Vidarabine; C024352:fludarabine